DK2219647T3 - Terapeutiske anvendelser af forbindelser med kombineret sert-, 5-HT3- og 5-HT1A-aktivitet - Google Patents

Terapeutiske anvendelser af forbindelser med kombineret sert-, 5-HT3- og 5-HT1A-aktivitet

Info

Publication number: DK2219647T3
Authority: DK; Denmark
Prior art keywords: compounds; therapeutic uses; ht1a activity; sert; combined
Prior art date: 2007-11-13

Application number

DK08850935.1T

Other languages

English (en)

Other versions

DK2219647T4 (da

Inventor

Marianne Dragheim

Aneil Batra

Nicholas Moore

Jin Chon

Original Assignee

Lundbeck & Co As H

Takeda Pharmaceuticals North America Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-11-13

Filing date

2008-11-12

Publication date

2012-03-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40170671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2219647(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-11-12 Application filed by Lundbeck & Co As H, Takeda Pharmaceuticals North America Inc filed Critical Lundbeck & Co As H

2012-03-19 Publication of DK2219647T3 publication Critical patent/DK2219647T3/da

2020-09-28 Application granted granted Critical

2020-09-28 Publication of DK2219647T4 publication Critical patent/DK2219647T4/da

Links

102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 title 1
101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
230000000694 effects Effects 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Gynecology & Obstetrics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Addiction (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Anesthesiology (AREA)
Nutrition Science (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK08850935.1T 2007-11-13 2008-11-12 Terapeutiske anvendelser af forbindelser med kombineret sert-, 5-ht3- og 5-ht1a-aktivitet DK2219647T4 (da)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US98771007P	2007-11-13	2007-11-13
DKPA200701607		2007-11-13
US1372207P	2007-12-14	2007-12-14
DKPA200701788		2007-12-14
US9784008P	2008-09-17	2008-09-17
DKPA200801300		2008-09-17
PCT/DK2008/050271 WO2009062517A1 (en)	2007-11-13	2008-11-12	Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity

Publications (2)

Publication Number	Publication Date
DK2219647T3 true DK2219647T3 (da)	2012-03-19
DK2219647T4 DK2219647T4 (da)	2020-09-28

Family

ID=40170671

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK08850935.1T DK2219647T4 (da)	2007-11-13	2008-11-12	Terapeutiske anvendelser af forbindelser med kombineret sert-, 5-ht3- og 5-ht1a-aktivitet
DK11193237.2T DK2431039T3 (da)	2007-11-13	2008-11-12	Terapeutisk anvendelse af forbindelser med kombineret sert-, 5-HT3 og 5-HT1A-aktivitet

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK11193237.2T DK2431039T3 (da)	2007-11-13	2008-11-12	Terapeutisk anvendelse af forbindelser med kombineret sert-, 5-HT3 og 5-HT1A-aktivitet

Country Status (30)

Country	Link
US (5)	US9278096B2 (da)
EP (3)	EP3115050A1 (da)
JP (2)	JP5603244B2 (da)
KR (1)	KR101536023B1 (da)
CN (1)	CN102014908A (da)
AR (1)	AR069260A1 (da)
AT (1)	ATE537829T1 (da)
AU (1)	AU2008323390B2 (da)
BR (1)	BRPI0820474B8 (da)
CA (1)	CA2705163C (da)
CL (1)	CL2008003363A1 (da)
CO (1)	CO6270322A2 (da)
CY (2)	CY1112646T1 (da)
DK (2)	DK2219647T4 (da)
EA (1)	EA027783B1 (da)
ES (2)	ES2591110T3 (da)
HR (2)	HRP20120144T4 (da)
HU (1)	HUE029588T2 (da)
IL (1)	IL205466A (da)
LT (1)	LT2431039T (da)
MX (1)	MX2010004688A (da)
NZ (1)	NZ585247A (da)
PL (2)	PL2431039T3 (da)
PT (2)	PT2219647E (da)
RS (2)	RS55147B1 (da)
SG (1)	SG10201405001XA (da)
SI (2)	SI2219647T2 (da)
TW (1)	TW200932233A (da)
WO (1)	WO2009062517A1 (da)
ZA (1)	ZA201003350B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200932233A (en)	2007-11-13	2009-08-01	Lundbeck & Co As H	Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
CA2769872A1 (en)	2009-08-24	2011-03-03	H. Lundbeck A/S	New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
TW201212918A (en)	2010-08-23	2012-04-01	Lundbeck & Co As H	Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
LT2667715T (lt) *	2011-01-27	2017-11-10	Neuren Pharmaceuticals Limited	Autizmo spektro susirgimų gydymas, naudojant glicil-l-2-metilprolil-l-glutamo rūgštį
WO2013012038A1 (ja)	2011-07-21	2013-01-24	学校法人名城大学	うつ病決定方法、セロトニントランスポーター分析キット及び血中ユビキチン化セロトニントランスポーター分析キット
US9211288B2 (en) *	2012-12-13	2015-12-15	H. Lundbeck A/S	Compositions comprising vortioxetine and donepezil
JP6323979B2 (ja) *	2013-01-17	2018-05-16	学校法人名城大学	うつ病マーカー、アッセイ方法、測定方法、うつ病薬のスクリーニング方法及びキット
CN105339361A (zh) *	2013-05-31	2016-02-17	斯洛文尼亚莱柯制药股份有限公司	用于合成1-(2-((2，4-二甲基苯基)硫代)苯基)哌嗪的新方法
EP2878596A1 (en) *	2013-11-29	2015-06-03	LEK Pharmaceuticals d.d.	Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
CA2933733A1 (en) *	2013-12-20	2015-06-25	Connie Sanchez Morillo	Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
CN103788019B (zh) *	2014-01-22	2015-10-07	苏州明锐医药科技有限公司	沃替西汀的制备方法
EA029060B1 (ru)	2014-01-31	2018-02-28	Эгиш Дьёдьсердьяр Зрт.	Способ получения солей вортиоксетина
EP2930171A1 (en) *	2014-04-07	2015-10-14	LEK Pharmaceuticals d.d.	Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate
CN104119298B (zh) *	2014-08-13	2016-08-24	北京蓝贝望生物医药科技股份有限公司	氢溴酸沃赛汀或氢溴酸沃替西汀
CN104119299B (zh) *	2014-08-13	2016-08-17	北京蓝贝望生物医药科技股份有限公司	沃赛汀或沃替西汀的氢溴酸盐
CN104610195B (zh) *	2015-01-30	2017-06-27	上虞京新药业有限公司	沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
JO3456B1 (ar) *	2015-05-13	2020-07-05	H Lundbeck As	فيروتيوكسيتين بيروجلوتامات
EP3799873A1 (en) *	2015-07-17	2021-04-07	Institut Pasteur	5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
MA45532A (fr)	2016-07-01	2019-05-08	H Lundbeck As	Schémas posologiques de la vortioxétine destinés à une apparition rapide de l'effet antidépresseur
US20210393621A1 (en)	2018-10-26	2021-12-23	The Research Foundation For The State University Of New York	Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
JP7874549B2 (ja)	2020-04-03	2026-06-16	ハー・ルンドベック・アクチエゼルスカベット	感情鈍麻の予防又は処置のための１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
WO2023036820A1 (en)	2021-09-10	2023-03-16	H. Lundbeck A/S	Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
KR20230148676A (ko)	2022-04-18	2023-10-25	영진약품 주식회사	라베프라졸 및 탄산수소나트륨을 포함하는 조성물 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
YU163075A (en) *	1975-07-21	1982-05-31	Science Union & Cie	Process for preparing new phenoxy derivatives
US5258387A (en)	1990-08-21	1993-11-02	Hoffmann-La Roche Inc.	Tricyclic pyridone derivatives
UA81749C2 (uk)	2001-10-04	2008-02-11	Х. Луннбек А/С	Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
EP1458689B1 (en) *	2001-12-20	2007-04-11	H. Lundbeck A/S	Aryloxyphenyl and arylsulfanylphenyl derivatives
WO2004087156A1 (en)	2003-04-04	2004-10-14	H. Lundbeck A/S	4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
US20060019938A1 (en)	2003-12-31	2006-01-26	Beer Tomasz M	Estrogen administration for treating male cognitive dysfunction or improving male cognitive function
MY150647A (en) *	2006-06-16	2014-02-14	Lundbeck & Co As H	1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
TW200848411A (en) *	2007-03-20	2008-12-16	Lundbeck & Co As H	Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) *	2007-11-13	2009-08-01	Lundbeck & Co As H	Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
CA2769872A1 (en)	2009-08-24	2011-03-03	H. Lundbeck A/S	New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine

2008
- 2008-11-03 TW TW097142306A patent/TW200932233A/zh unknown
- 2008-11-11 AR ARP080104919A patent/AR069260A1/es unknown
- 2008-11-12 MX MX2010004688A patent/MX2010004688A/es active IP Right Grant
- 2008-11-12 BR BRPI0820474A patent/BRPI0820474B8/pt active IP Right Grant
- 2008-11-12 WO PCT/DK2008/050271 patent/WO2009062517A1/en not_active Ceased
- 2008-11-12 PT PT08850935T patent/PT2219647E/pt unknown
- 2008-11-12 JP JP2010533436A patent/JP5603244B2/ja active Active
- 2008-11-12 PL PL11193237.2T patent/PL2431039T3/pl unknown
- 2008-11-12 LT LTEP11193237.2T patent/LT2431039T/lt unknown
- 2008-11-12 EA EA201070598A patent/EA027783B1/ru not_active IP Right Cessation
- 2008-11-12 EP EP16178423.6A patent/EP3115050A1/en not_active Withdrawn
- 2008-11-12 AT AT08850935T patent/ATE537829T1/de active
- 2008-11-12 DK DK08850935.1T patent/DK2219647T4/da active
- 2008-11-12 RS RS20160756A patent/RS55147B1/sr unknown
- 2008-11-12 NZ NZ585247A patent/NZ585247A/en not_active IP Right Cessation
- 2008-11-12 SG SG10201405001XA patent/SG10201405001XA/en unknown
- 2008-11-12 DK DK11193237.2T patent/DK2431039T3/da active
- 2008-11-12 SI SI200830548T patent/SI2219647T2/sl unknown
- 2008-11-12 CN CN2008801164637A patent/CN102014908A/zh active Pending
- 2008-11-12 PL PL08850935T patent/PL2219647T3/pl unknown
- 2008-11-12 EP EP08850935.1A patent/EP2219647B2/en active Active
- 2008-11-12 EP EP11193237.2A patent/EP2431039B1/en active Active
- 2008-11-12 ES ES11193237.2T patent/ES2591110T3/es active Active
- 2008-11-12 CL CL2008003363A patent/CL2008003363A1/es unknown
- 2008-11-12 SI SI200831677A patent/SI2431039T1/sl unknown
- 2008-11-12 AU AU2008323390A patent/AU2008323390B2/en active Active
- 2008-11-12 US US12/741,780 patent/US9278096B2/en active Active
- 2008-11-12 HR HRP20120144TT patent/HRP20120144T4/hr unknown
- 2008-11-12 CA CA2705163A patent/CA2705163C/en active Active
- 2008-11-12 HU HUE11193237A patent/HUE029588T2/en unknown
- 2008-11-12 PT PT111932372T patent/PT2431039T/pt unknown
- 2008-11-12 ES ES08850935T patent/ES2379419T5/es active Active
- 2008-11-12 KR KR1020107010492A patent/KR101536023B1/ko not_active Ceased
- 2008-11-12 RS RS20120087A patent/RS52256B2/sr unknown
2010
- 2010-04-29 IL IL205466A patent/IL205466A/en active IP Right Grant
- 2010-05-12 ZA ZA2010/03350A patent/ZA201003350B/en unknown
- 2010-05-13 CO CO10057476A patent/CO6270322A2/es not_active Application Discontinuation
2012
- 2012-02-24 CY CY20121100199T patent/CY1112646T1/el unknown
2014
- 2014-05-14 JP JP2014100815A patent/JP5841636B2/ja active Active
2016
- 2016-02-12 US US15/043,167 patent/US9744166B2/en active Active
- 2016-09-01 HR HRP20161121TT patent/HRP20161121T1/hr unknown
- 2016-09-07 CY CY20161100885T patent/CY1117978T1/el unknown
2017
- 2017-07-27 US US15/661,392 patent/US20180161321A1/en not_active Abandoned
2020
- 2020-05-12 US US15/930,014 patent/US11628166B2/en active Active
2023
- 2023-04-04 US US18/130,749 patent/US20240082239A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR101536023B1 (ko)	2015-07-10
BRPI0820474A2 (pt)	2017-05-23
CN102014908A (zh)	2011-04-13
PT2219647E (pt)	2012-03-16
EP2431039A1 (en)	2012-03-21
EP2431039B1 (en)	2016-07-20
ES2591110T3 (es)	2016-11-24
CY1112646T1 (el)	2016-02-10
EP2219647B1 (en)	2011-12-21
IL205466A0 (en)	2010-12-30
ZA201003350B (en)	2011-08-31
US11628166B2 (en)	2023-04-18
ES2379419T3 (es)	2012-04-25
JP2014193891A (ja)	2014-10-09
RS52256B2 (sr)	2020-11-30
ES2379419T5 (es)	2021-05-04
RS52256B (sr)	2012-10-31
PT2431039T (pt)	2016-09-29
CA2705163C (en)	2013-02-12
SI2219647T1 (sl)	2012-06-29
HRP20120144T4 (hr)	2020-11-13
PL2431039T3 (pl)	2016-12-30
CA2705163A1 (en)	2009-05-22
EP2219647A1 (en)	2010-08-25
KR101536023B9 (ko)	2023-03-29
HRP20161121T1 (hr)	2017-01-27
MX2010004688A (es)	2010-09-09
US20240082239A1 (en)	2024-03-14
JP5603244B2 (ja)	2014-10-08
CY1117978T1 (el)	2017-05-17
HRP20120144T1 (en)	2012-04-30
NZ585247A (en)	2012-03-30
TW200932233A (en)	2009-08-01
LT2431039T (lt)	2016-10-10
SG10201405001XA (en)	2014-10-30
AU2008323390B2 (en)	2013-10-24
ATE537829T1 (de)	2012-01-15
EP2219647B2 (en)	2020-07-29
DK2431039T3 (da)	2016-09-26
WO2009062517A1 (en)	2009-05-22
EA201070598A1 (ru)	2010-10-29
BRPI0820474B1 (pt)	2020-08-04
BRPI0820474B8 (pt)	2021-05-25
AU2008323390A1 (en)	2009-05-22
IL205466A (en)	2014-06-30
US20110201617A1 (en)	2011-08-18
EP3115050A1 (en)	2017-01-11
US9278096B2 (en)	2016-03-08
RS55147B1 (sr)	2016-12-30
DK2219647T4 (da)	2020-09-28
HUE029588T2 (en)	2017-03-28
PL2219647T3 (pl)	2012-07-31
US20180161321A1 (en)	2018-06-14
KR20100099115A (ko)	2010-09-10
CL2008003363A1 (es)	2009-06-05
JP5841636B2 (ja)	2016-01-13
US20160228430A1 (en)	2016-08-11
AR069260A1 (es)	2010-01-06
JP2011503125A (ja)	2011-01-27
US9744166B2 (en)	2017-08-29
SI2219647T2 (sl)	2020-11-30
CO6270322A2 (es)	2011-04-20
SI2431039T1 (sl)	2017-01-31
EA027783B1 (ru)	2017-09-29
US20210093631A1 (en)	2021-04-01

Publication	Publication Date	Title
DK2219647T4 (da)	2020-09-28	Terapeutiske anvendelser af forbindelser med kombineret sert-, 5-ht3- og 5-ht1a-aktivitet
FIC20220033I1 (fi)	2022-08-05	Finerenoni sekä sen suolat, solvaatit ja suolojen solvaatit
DK2191831T3 (da)	2011-06-20	Modificering af pirfenidon-behandling for patienter med atypisk leverfunktion
DK2117523T3 (da)	2014-09-08	Inhibitorer af AKT-aktivitet
DK2211901T3 (da)	2013-07-08	Vaccination med multiple clader af h5-influenza-a-virus
DK2250161T3 (da)	2014-01-27	Forbindelser med CRTH2-antagonistaktivitet
DK3456707T3 (da)	2020-07-20	4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
SMT201600203B (it)	2016-08-31	Enantiomeri di composti spiro-ossindolici e loro usi come agenti terapeutici
DK2222272T3 (da)	2013-02-11	Behandling af luftvejssygdom
DK3225251T3 (da)	2020-03-16	Modulering af pro-neurotrofinaktivitet
DK2350416T4 (da)	2019-07-15	Multipel rude med mindst én antirefleksbehandling og anvendelse af antirefleksbehandling i multipel rude
BR112013013790A2 (pt)	2016-09-13	compostos heterocíclos nitrogenosos 6,6-fundidos substituídos e usos dos mesmos
EP2181409A4 (en)	2013-10-02	FIELD DEVICE COMPENSATION PERFORMING TEMPERATURE MEANS
DK2504005T3 (da)	2014-01-13	Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
PL2296464T3 (pl)	2015-08-31	Sole i polimorfy związku tetracyklinowego
DK2848610T3 (da)	2017-11-06	Hæmmere af kinaseaktivitet
DK3192520T3 (da)	2019-05-27	Terapeutiske midler til reducering af niveauerne af parathyreoideahormon
DK2346408T3 (da)	2014-07-21	Overvågning af fosterhjerteaktivitet
BR112012000735A2 (pt)	2016-11-16	"métodos, kits e conjuntos de compostos"
DK1981506T3 (da)	2013-06-24	Langtidsbehandling af HIV-infektion med TMC278
DK1890684T3 (da)	2013-10-14	Behandling af søvn/vågenhedsforstyrrelser
DK2324013T3 (da)	2012-11-19	Broforbundne piperidinforbindelser af substitueret quinoxalintype og anvendelser deraf
DK2498771T3 (da)	2014-01-27	Anvendelse af bethanechol til behandling af xerostomi
NO345064B1 (no)	2020-09-14	Anvendelse av kombinasjonslegemidler, omfattende antimykotika
DK2411009T3 (da)	2013-06-24	Terapeutiske anvendelser af quinazolindionderivater